Table 1.
Demographic characteristics of participants at first evaluable visit according to emtricitabine triphosphate (FTC-TP) in dried blood spots (DBS). All values are expressed as median (IQR) or n (%).
| FTC-TP in DBS | |||
|---|---|---|---|
| Characteristic | All Participants (n=433) |
BLQ* (n=41) |
Quantifiable (n=392) |
| Age | 46 (37, 52) | 43 (34, 50) | 46 (38, 53) |
| Gender | |||
| Male | 364 (84%) | 33 (80%) | 331 (84%) |
| Female | 69 (16%) | 8 (20%) | 61 (16%) |
| Race/Ethnicity | |||
| Black | 83 (19%) | 9 (22%) | 74 (19%) |
| White | 246 (57%) | 19 (46%) | 227 (58%) |
| Hispanic | 85 (20%) | 12 (29%) | 73 (19%) |
| Other | 19 (4%) | 1 (2%) | 18 (5%) |
| Body Mass Index (Kg/m2) | |||
| <18.5 | 18 (4%) | 1 (2%) | 17 (4%) |
| 18.5-25 | 183 (42%) | 19 (46%) | 164 (42%) |
| 25-30 | 146 (34%) | 14 (34%) | 132 (34%) |
| >30 | 86 (20%) | 7 (14%) | 79 (20%) |
| eGFR (mL/min/1.73 m2) | 87 (73, 101) | 98 (81, 112) | 86 (73, 100) |
| CD4+ T-cell count (cells/mm3) | |||
| <200 | 47 (11%) | 9 (22%) | 38 (10%) |
| 200-350 | 62 (14%) | 6 (15%) | 56 (14%) |
| 350-500 | 64 (15%) | 8 (20%) | 56 (14%) |
| >500 | 260 (60%) | 18 (44%) | 242 (62%) |
| HIV viral load (copies/mL)** | 117 (36, 710) | 6620 (352, 35,600) | 67 (32, 189) |
| Hematocrit (%) | 45 (42, 47) | 44 (40, 46) | 45 (42, 47) |
| Type of ART | |||
| NNRTI-based | 118 (27%) | 3 (7%) | 115 (29%) |
| INSTI-based | 155 (36%) | 15 (37%) | 140 (36%) |
| b/PI-based | 106 (24%) | 14 (34%) | 92 (23%) |
| Multiclass | 54 (12%) | 9 (22%) | 45 (11%) |
| TFV-DP in DBS category (fmol/punch) | |||
| <800 | 55 (13%) | 26 (63%) | 29 (7%) |
| 800-1650 | 156 (36%) | 12 (29%) | 144 (37%) |
| ≥1650 | 222 (51%) | 3 (7%) | 219 (56%) |
| Self-reported adherence (%) | |||
| 3-day | 100 (100, 100) | 100 (10, 100) | 100 (100, 100) |
| 30-day | 100 (94,100) | 90 (50, 95) | 100 (95, 100) |
| 3-month | 98 (90,100) | 80 (50, 90) | 99 (90,100) |
FTC-TP: emtricitabine triphosphate; TFV-DP: tenofovir diphosphate; DBS: dried blood spots; ART: antiretroviral therapy; NNRTI: non-nucleoside reverse transcriptase inhibitor; INSTI: integrase strand-transfer inhibitor; b/PI: boosted protease inhibitor.
*
FTC-TP in DBS was considered BLQ if it was <0.1 pmol/sample.
**
HIV viral load for viremic participants (≥20 copies/mL).